The Manufacturers Life Insurance Company Has $416.73 Million Stake in Amgen Inc. $AMGN

The Manufacturers Life Insurance Company lowered its holdings in Amgen Inc. (NASDAQ:AMGN) by 8.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,150,794 shares of the medical research company’s stock after selling 107,249 shares during the period. The Manufacturers Life Insurance Company’s holdings in Amgen were worth $416,725,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Trajan Wealth LLC lifted its position in Amgen by 38.5% during the 2nd quarter. Trajan Wealth LLC now owns 24,096 shares of the medical research company’s stock worth $8,726,000 after buying an additional 6,700 shares in the last quarter. Van Hulzen Asset Management LLC increased its position in shares of Amgen by 9.2% in the second quarter. Van Hulzen Asset Management LLC now owns 6,577 shares of the medical research company’s stock valued at $2,382,000 after acquiring an additional 552 shares during the last quarter. Verity Asset Management Inc. increased its position in shares of Amgen by 6.2% in the second quarter. Verity Asset Management Inc. now owns 8,729 shares of the medical research company’s stock valued at $3,161,000 after acquiring an additional 511 shares during the last quarter. Fiduciary Financial Advisors bought a new stake in Amgen during the second quarter worth about $404,000. Finally, Manning & Napier Advisors LLC raised its holdings in Amgen by 147.5% during the second quarter. Manning & Napier Advisors LLC now owns 448 shares of the medical research company’s stock worth $162,000 after acquiring an additional 267 shares in the last quarter. 76.50% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

AMGN has been the subject of a number of analyst reports. Barclays raised their price target on Amgen from $360.00 to $380.00 and gave the company an “equal weight” rating in a research note on Friday, August 14th. The Goldman Sachs Group set a $389.00 price objective on Amgen in a research note on Friday, June 5th. Canaccord Genuity Group increased their price objective on Amgen from $366.00 to $384.00 and gave the company a “hold” rating in a report on Wednesday, August 5th. Wells Fargo & Company raised their target price on shares of Amgen from $390.00 to $400.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 5th. Finally, Citigroup boosted their target price on shares of Amgen from $345.00 to $405.00 and gave the stock a “neutral” rating in a report on Friday, August 7th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, fourteen have given a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat, Amgen presently has an average rating of “Hold” and an average price target of $380.43.

Amgen Price Performance

Shares of NASDAQ AMGN opened at $443.84 on Tuesday. The business’s 50 day moving average price is $380.90 and its two-hundred day moving average price is $362.81. The company has a market cap of $239.95 billion, a PE ratio of 27.58, a price-to-earnings-growth ratio of 3.17 and a beta of 0.41. The company has a quick ratio of 1.13, a current ratio of 1.37 and a debt-to-equity ratio of 4.44. Amgen Inc. has a twelve month low of $269.77 and a twelve month high of $445.87.

Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, topping the consensus estimate of $5.62 by $0.67. The company had revenue of $10.05 billion during the quarter, compared to the consensus estimate of $9.43 billion. Amgen had a return on equity of 124.14% and a net margin of 22.95%.The firm’s revenue for the quarter was up 9.5% compared to the same quarter last year. During the same period in the previous year, the company posted $6.02 EPS. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, analysts predict that Amgen Inc. will post 22.92 EPS for the current year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 11th. Shareholders of record on Friday, August 21st will be given a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date of this dividend is Friday, August 21st. Amgen’s payout ratio is 62.65%.

Insider Buying and Selling at Amgen

In related news, SVP Rachna Khosla sold 2,000 shares of the company’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $412.57, for a total value of $825,140.00. Following the transaction, the senior vice president owned 6,404 shares in the company, valued at approximately $2,642,098.28. This represents a 23.80% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Nancy A. Grygiel sold 2,970 shares of the stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the completion of the transaction, the senior vice president directly owned 7,340 shares in the company, valued at approximately $2,951,854.40. This represents a 28.81% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 6,222 shares of company stock worth $2,540,926. Corporate insiders own 0.85% of the company’s stock.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.